Mesalamine is generally considered safe to take during pregnancy. It carries a low-risk classification for pregnant women, and major gastroenterology guidelines recommend continuing it to keep inflammatory bowel disease in remission throughout pregnancy. The bigger risk, in most cases, is stopping the medication and allowing a flare.
Why Continuing Treatment Usually Matters More
The core concern during pregnancy isn’t the medication itself but what happens without it. When IBD is active during pregnancy, studies have found higher rates of preterm birth and low birth weight. Some research also links active disease at the time of conception to increased fetal loss. Keeping your disease in remission before and during pregnancy gives you the best chance of a healthy outcome, and mesalamine is one of the primary tools for doing that.
European Crohn’s and Colitis Organisation (ECCO) guidelines list mesalamine preparations among the safest medications for use during pregnancy and breastfeeding, alongside a small number of other IBD drugs. The rate of congenital anomalies in babies born to mothers who took mesalamine has not been higher than the rate in the general population across multiple studies.
What Happens in Your Body
Mesalamine does cross the placenta. In one detailed case, the drug’s concentration in umbilical cord blood was roughly one quarter of the mother’s level, and its main breakdown product reached similar concentrations in both. By 21 to 30 hours after birth, the drug was no longer detectable in the newborn’s blood, and the breakdown product dropped to trace levels. So the fetus is exposed, but the exposure clears quickly after delivery.
Rare complications have been reported. A small number of case reports describe allergic-type reactions in newborns, including gastrointestinal bleeding that resolved after birth. One case report linked doses above 3 grams per day to kidney inflammation in a newborn. These are isolated reports, not patterns seen in larger studies, but they’re part of why your prescriber may pay attention to dosing.
Which Formulation You Take Matters
Not all mesalamine pills are identical. The older formulations sold as Asacol and Asacol HD contain a coating ingredient called dibutyl phthalate (DBP), a chemical that has raised concerns about reproductive health. Research has linked DBP exposure from these specific formulations to disrupted reproductive hormones and decreased sperm motility in men, and phthalates in general are flagged as potential risks during fetal development.
Other mesalamine formulations, including Pentasa, Lialda, Apriso, and Delzicol, do not contain DBP. If you’re currently taking an Asacol formulation, it’s worth discussing a switch with your prescriber. The active drug is the same across all versions; the difference is only in the coating.
Folic Acid and Sulfasalazine
If you take sulfasalazine rather than a standard mesalamine product, folic acid supplementation becomes especially important. Sulfasalazine interferes with your body’s ability to absorb folic acid by blocking an enzyme involved in folate processing. Since folic acid is critical for preventing neural tube defects in early pregnancy, supplementation is strongly recommended for anyone on sulfasalazine, ideally starting before conception. Standard mesalamine formulations don’t have this same effect on folate absorption, but a prenatal vitamin with folic acid is still part of routine pregnancy care.
Doses to Be Aware Of
At conventional doses, mesalamine has not been associated with increased birth defects in studies. The signal for concern appears at higher doses. The case of neonatal kidney problems involved a daily dose above 3 grams. Most maintenance regimens for ulcerative colitis fall within a range your prescriber can evaluate against your specific disease severity. The goal is using the lowest effective dose that keeps your disease quiet, which is the same principle that applies outside of pregnancy.
Breastfeeding After Delivery
Mesalamine enters breast milk in very small amounts. The average infant exposure through milk is about 0.02% of the mother’s weight-adjusted dose, which is extremely low. A few cases of mild diarrhea in nursing infants have been reported, but the rate is not considered high, and most infants tolerate it without issues. Guidelines generally classify mesalamine as probably compatible with breastfeeding.
What We Don’t Yet Know
No studies have specifically tracked whether children exposed to mesalamine in utero show differences in learning, behavior, or long-term development. This isn’t because problems have been suspected; it’s simply a gap in the research. The absence of red flags in the data we do have is reassuring, but it’s worth knowing that this particular question hasn’t been formally studied.